Compound Semaglutide
US$ 24.14
surpass cvot tirzepatide SURPASS-CVOT trial: was non-inferior to dulaglutide and superior to putative placebo for reducing the composite of CV death/HF events in patients with T2D and ASCVD. #AHA25 View the slides here: https://t.co/6VQpBHFP2I SURPASS-CVOT trial: For patients with
Description
Helps reduce appetite and slows how quickly the stomach empties
now, millions of people are using it to lose weight
GLP-1 RA use was consistently associated with improvements in headache frequency, weight reduction, and reduced need for acetazolamide or surgical interventions
Resmetirom approval and promising incretin-based therapies reshape the treatment landscape for liver and cardiometabolic outcomes.
You need something that works when your appetite is low, your schedule is full, and your motivation isnt perfect
